Company: CWAN
Filing Date: 2025-03-06
Form Type: S-4/A
Source: 0001193125-25-048570
Chunk: 46

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-06
Form: S-4/A
Chunk 46
---
 page 179)

Enfusion Stockholders who do not vote in favor of approval of the Merger Agreement Proposal, who continuously hold their shares of
Enfusion Common Stock or Enfusion Class B Common Stock through the Effective Time and who otherwise comply precisely with the applicable provisions of Section 262 of the DGCL will be entitled to seek appraisal of the fair value of their
shares of Enfusion Common Stock or Enfusion Class B Common Stock, as determined by the Delaware Court of Chancery, if the Merger is completed. The “fair value” of your shares of Enfusion Common Stock or Enfusion Class B Common
Stock as determined by the Delaware Court of Chancery could be greater than, the same as, or less than the value of the Merger Consideration that you would otherwise be entitled to receive under the terms of the Merger Agreement. Enfusion
Stockholders who wish to exercise the right to seek an appraisal of their shares must so advise Enfusion by submitting a written demand for appraisal in the form described in this Proxy Statement/Prospectus prior to the vote to approve the Merger
Agreement Proposal, and must otherwise follow the procedures prescribed by Section 262 of the DGCL. A person having a beneficial interest in shares of Enfusion Common Stock or Enfusion Class B Common Stock held of record in the name of
another person, such as a nominee or intermediary, must follow additional steps summarized in this Proxy Statement/Prospectus and in a timely manner to perfect appraisal rights.

The text of Section 262 of the DGCL is attached as Annex E to this Proxy Statement/Prospectus. You are encouraged to read these
provisions carefully and in their entirety. Due to the complexity of the procedures for exercising appraisal rights, Enfusion Stockholders who are considering exercising such rights are encouraged to seek the advice of legal counsel and their
financial advisors. Failure to strictly comply with these provisions may result in the loss of appraisal rights.

No Solicitation of Other Offers by Enfusion(see page 132)

Under the terms of the Merger Agreement, Enfusion has agreed not to solicit, encourage or
facilitate any competing acquisition proposals for Enfusion, enter into discussions or negotiations with any third parties regarding any competing acquisition proposals for Enfusion or enter into any agreements with a third party regarding any
competing acquisition proposals for Enfusion.

Notwithstanding the foregoing restrictions, if prior to Enfusion Stockholders adopting the
Merger Agreement at the Special Meeting Enfusion receives an unsolicited